Cochrane · systematic review · CD013653
Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive pregnant women co‐infected with hepatitis B virus
Ugwu, EO, Eleje, GU, Ugwu, AO, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 40%Very low 3 · 60%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tenofovir‐based antiviral combination regimens versus placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus‐positive pregnant women co‐infected with hepatitis B virus
Population: HIV‐positive pregnant women co‐infected with hepatitis B virus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause infant mortality at longest Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens | RR 2.24 [0.72, 6.96] | 1 study · 132 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of infants with serious adverse events ( Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens | RR 1.76 [1.27, 2.43] | 1 study · 132 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of infants with HBV mother‐to‐child transmission Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens | no estimate extracted | 0 studies · 0 participants | Ungraded |
All‐cause maternal mortality at the longest Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens | no estimate extracted | 0 studies · 0 participants | Ungraded |
Proportion of mothers with serious adverse events ( Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens | RR 0.9 [0.62, 1.32] | 2 studies · 270 participants | Very low Downgraded: risk of bias, imprecision |